ADVM Live signals | Maximize Profits with Getagraph.com

BUY 95039 min ago

@ $2.19

Issued: 14 Feb 2024 @ 09:34

Return: 417.81%

Previous signal: Feb 12 - 16:00

Previous signal: Sell

Return: 10.05 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	115 610
Average Volume	273 368
Market Cap	235.36M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-1.300 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.980
ATR14	$0.0200 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-03	Seyedkazemi Setareh	Buy	85 000	Stock Option (Right to Buy)
2023-10-03	Soparkar Peter	Buy	130 000	Stock Option (Right to Buy)
2023-10-03	Fischer Laurent	Buy	315 000	Stock Option (Right to Buy)
2024-02-12	Seyedkazemi Setareh	Buy	400 000	Stock Option (Right to Buy)
2024-02-12	Fischer Laurent	Buy	1 104 200	Stock Option (Right to Buy)

INSIDER POWER
96.94
Last 100 transactions
Buy: 14 665 896 \| Sell: 1 551 540

Volume Correlation

Long: 0.17 (neutral)

Short: 0.64 (weak)

Signal:(71.283) Neutral

Adverum Biotechnologies Correlation

10 Most Positive Correlations
RVNC	0.965
VCNX	0.964
LYT	0.963
SBET	0.959
RSLS	0.957
HA	0.957
BCLI	0.956
FDMT	0.955
STKS	0.954
TNYA	0.953

10 Most Negative Correlations
RMRM	-0.971
ACQR	-0.963
TBSA	-0.962
HERA	-0.962
NVSA	-0.961
FRSG	-0.961
LEGA	-0.96
FTPA	-0.96
GXII	-0.96
AGGR	-0.96

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Adverum Biotechnologies Correlation - Currency/Commodity

0.55
( weak )

0.49
( neutral )

0.00
( neutral )

0.60
( weak )

-0.73
( moderate negative )

-0.38
( neutral )

Adverum Biotechnologies Financials

Annual	2023
Revenue:	$3.60M
Gross Profit:	$-2.04M (-56.78 %)
EPS:	$-11.62

Q4	2023
Revenue:	$0
Gross Profit:	$-1.01M (0.00 %)
EPS:	$-2.34

Q3	2023
Revenue:	$0
Gross Profit:	$-1.51M (0.00 %)
EPS:	$-3.26

Q2	2023
Revenue:	$0
Gross Profit:	$-7.04M (0.00 %)
EPS:	$-3.13

Financial Reports:

No articles found.

Adverum Biotechnologies

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.